Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
30 avr. 2024 01h00 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement...
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
22 avr. 2024 01h00 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in EuropeEC approval based on robust development program...
Sandoz receives FDA approval for first and only denosumab biosimilars
05 mars 2024 13h24 HE
|
Sandoz Group
MEDIA RELEASE Wyost® (denosumab-bddz) and Jubbonti® (denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva ®* (denosumab) and Prolia®*...
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
04 mars 2024 01h00 HE
|
Sandoz Group
MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab injection) for all approved indicationsDedicated retina sales and field reimbursement team...
Biosimilars Market is Projected to Surpass USD 85 billion by 2031, Growing at CAGR 15.5%- Report by Transparency Market Research, Inc.
15 févr. 2024 09h35 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global biosimilars market is estimated to flourish at a CAGR of 15.5% from 2022 to...
Biologics Contract Development & Manufacturing Organization Market revenue to hit USD 39 Billion by 2036, says Research Nester
08 févr. 2024 05h30 HE
|
Research Nester
New York, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The global biologics contract development & manufacturing organization (CDMO) market size is projected to grow at a CAGR of over ~12% from 2024 to...
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
31 janv. 2024 01h00 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Tyruko® approved for all indications of reference medicine Tyruko® biosimilar to treat...
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market
22 janv. 2024 01h00 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®**...
Microbial Fermentation Technology Market revenue to hit USD 63 Billion by 2036, says Research Nester
06 déc. 2023 06h00 HE
|
Research Nester
New York , Dec. 06, 2023 (GLOBE NEWSWIRE) -- The global microbial fermentation technology market size is expected to expand at 6% CAGR from 2024 to 2036. The market is anticipated to garner a...
Biosimilars Market To Reach USD 143.7 Billion By 2032 Report By DataHorizzon Research
18 oct. 2023 08h00 HE
|
DataHorizzon Research
Fort Collins, Colorado, Oct. 18, 2023 (GLOBE NEWSWIRE) -- According to DataHorizzon Research, the Biosimilars Market size was valued at USD 27.7 Billion in 2022 and is expected to have a market size...